Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA

INTRODUCTION: After a patient with rheumatoid arthritis (RA) fails tumor necrosis factor inhibitor (TNFi) treatment, clinical guidelines support either cycling to another TNFi or switching to a different mechanism of action (MOA), but payers often require TNFi cycling before they reimburse switching...

Descripción completa

Detalles Bibliográficos
Autores principales: Chastek, Benjamin, Chen, Chieh-I, Proudfoot, Clare, Shinde, Shraddha, Kuznik, Andreas, Wei, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702369/
https://www.ncbi.nlm.nih.gov/pubmed/29039054
http://dx.doi.org/10.1007/s12325-017-0617-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702369/
https://www.ncbi.nlm.nih.gov/pubmed/29039054
http://dx.doi.org/10.1007/s12325-017-0617-5

Ejemplares similares